The TLR7 agonist Imiquimod promote the immunogenicity of msenchymal stem cells

The TLR7 agonist Imiquimod promote the immunogenicity of msenchymal stem cells

BACKGROUND: Mesenchymal stem cells (MSCs) are considered the best candidate in stem cells therapy due to their multipotent differentiation ability, low expression of co-stimulatory molecules (CD80, CD86, CD34 and HLA-II) and immunosuppression effects on in vivo immune responses. MSCs were now widely...

Full description

Bibliographic Details
Main Authors: Li Zhang, Dan Liu, Dan Pu, Yanwen Wang, Li Li, Yanqi He, Yalun Li, Lei Li, Weimin Li
Format: Article
Language:English
Published: BMC 2015-01-01
Series:Biological Research
Subjects:
Mesenchymal stem cells
Umbilical cord
Toll like receptor 7
Immunogenicity
Pro-inflammatory molecules
Online Access:http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0716-97602015000100006&lng=en&tlng=en

Internet

http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0716-97602015000100006&lng=en&tlng=en

Similar Items